InterPAD - DETAILS

Cabozantinib, 849217-68-1, XL184, Cometriq, XL-184, XL 184, BMS-907351, XL-184 free base, BMS 907351, Cabozantinib (XL184, BMS-907351), CHEBI:72317, XL184 cpd, UNII-1C39JW444G, Cabozantinib [USAN], 1C39JW444G, BMS-907351 FREE BASE, N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE, DTXSID10233968, MFCD20926324, n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide, Cabozantinib (USAN), XL-184 (Cabozantinib,BMS907351), Cabometyx (TN), Cometriq (TN), 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, 1,1-CYCLOPROPANEDICARBOXAMIDE, N'-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N-(4-FLUOROPHENYL)-, 1,1-CYCLOPROPANEDICARBOXAMIDE, N-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)-, N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide, N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Cabozantinib [USAN:INN], cabozantinibum, Carbozantinib, Cabozantinib; N'-?[4-?[(6,?7-?Dimethoxy-?4-?quinolinyl)?oxy]?phenyl]?-?N-?(4-?fluorophenyl)?-1,?1-cyclopropanedicarbox?amide; N'-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; BMS 907351; N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide, N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Cabozantinib (free base), CABOZANTINIB [MI], Cabozantinib (XL-184), CABOZANTINIB [INN], CABOZANTINIB [VANDF], CABOZANTINIB [WHO-DD], SCHEMBL360795, GTPL5887, Cabozantinib (BMS-907351), CHEMBL2105717, DTXCID40156459, EX-A075, L01XE26, BCPP000308, HMS3654G06, XL-184 free base (Cabozantinib), BCP02591, 849217-68-1 (free base), BDBM50021574, NSC761068, NSC800066, s1119, AKOS025142112, BCP9000470, CCG-264678, CS-0278, DB08875, NSC-761068, NSC-800066, SB20062, XL-184,Cabozantinib, BMS-907351, NCGC00263164-01, NCGC00263164-14, NCGC00263164-17, AC-25082, AS-16277, HY-13016, N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide, SY097158, DB-023624, FT-0664184, NS00020240, SW218093-3, D10062, AB01565831_02, Q795057, SR-01000941569, J-523016, SR-01000941569-1, BRD-K51544265-001-01-8, XL184 , BMS-907351, 1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-, cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, cyclopropane-1,1-dicarboxylic acid[4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4 fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]-N inverted exclamation mark -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N1-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

No.	Title	Href
1	A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress. Redox Biol. 2023 Dec;68:102945. doi: 10.1016/j.redox.2023.102945.	`Click`
2	Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27. Front Oncol. 2023 Jan 6;12:1084884. doi: 10.3389/fonc.2022.1084884.	`Click`

No.

Title

Href

A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress. Redox Biol. 2023 Dec;68:102945. doi: 10.1016/j.redox.2023.102945.

Click

Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27. Front Oncol. 2023 Jan 6;12:1084884. doi: 10.3389/fonc.2022.1084884.

Click

Name	Cabozantinib
PubChem CID	25102847
Molecular Weight	501.5g/mol
Synonyms	Cabozantinib, 849217-68-1, XL184, Cometriq, XL-184, XL 184, BMS-907351, XL-184 free base, BMS 907351, Cabozantinib (XL184, BMS-907351), CHEBI:72317, XL184 cpd, UNII-1C39JW444G, Cabozantinib [USAN], 1C39JW444G, BMS-907351 FREE BASE, N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE, DTXSID10233968, MFCD20926324, n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide, Cabozantinib (USAN), XL-184 (Cabozantinib,BMS907351), Cabometyx (TN), Cometriq (TN), 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, 1,1-CYCLOPROPANEDICARBOXAMIDE, N'-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N-(4-FLUOROPHENYL)-, 1,1-CYCLOPROPANEDICARBOXAMIDE, N-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)-, N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide, N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Cabozantinib [USAN:INN], cabozantinibum, Carbozantinib, Cabozantinib; N'-?[4-?[(6,?7-?Dimethoxy-?4-?quinolinyl)?oxy]?phenyl]?-?N-?(4-?fluorophenyl)?-1,?1-cyclopropanedicarbox?amide; N'-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; BMS 907351; N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide, N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Cabozantinib (free base), CABOZANTINIB [MI], Cabozantinib (XL-184), CABOZANTINIB [INN], CABOZANTINIB [VANDF], CABOZANTINIB [WHO-DD], SCHEMBL360795, GTPL5887, Cabozantinib (BMS-907351), CHEMBL2105717, DTXCID40156459, EX-A075, L01XE26, BCPP000308, HMS3654G06, XL-184 free base (Cabozantinib), BCP02591, 849217-68-1 (free base), BDBM50021574, NSC761068, NSC800066, s1119, AKOS025142112, BCP9000470, CCG-264678, CS-0278, DB08875, NSC-761068, NSC-800066, SB20062, XL-184,Cabozantinib, BMS-907351, NCGC00263164-01, NCGC00263164-14, NCGC00263164-17, AC-25082, AS-16277, HY-13016, N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide, SY097158, DB-023624, FT-0664184, NS00020240, SW218093-3, D10062, AB01565831_02, Q795057, SR-01000941569, J-523016, SR-01000941569-1, BRD-K51544265-001-01-8, XL184 , BMS-907351, 1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-, cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, cyclopropane-1,1-dicarboxylic acid[4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4 fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]-N inverted exclamation mark -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N1-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Drug Type	Small molecule
Formula	C₂₈H₂₄FN₃O₅
SMILES	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
InChI	1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
InChIKey	ONIQOQHATWINJY-UHFFFAOYSA-N
CAS Number	849217-68-1
ChEMBL ID	CHEMBL2105717
ChEBI ID	CHEBI:72317
TTD ID	D0IQ6P
Drug Bank ID	DB08875
KEGG ID	D10062
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Honokiol, Cabozantinib
Partner Name	Honokiol
Disease Info	[ICD-11: 2C90.0]	Renal cell carcinoma		Investigative
Biological Phenomena	Induction-->Oxidative Stress
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	NFE2L2	hsa4780
	Down-regulation	Expression	RUBCN	hsa9711
	Down-regulation	Expression	SQSTM1	hsa8878
In Vitro Model	786-O	Renal cell carcinoma	Homo sapiens (Human)	CVCL_1051
	Caki-1	Clear cell renal cell carcinoma	Homo sapiens (Human)	CVCL_0234
	Caki-2	Papillary renal cell carcinoma	Homo sapiens (Human)	CVCL_0235
	ACHN	Papillary renal cell carcinoma	Homo sapiens (Human)	CVCL_1067
In Vivo Model	786-0 cells were subcutaneously injected into dorsal flank of 8-week-old male athymic nude mice and observed for the formation of tumors. The mice were then divided into four treatment groups (n = 5 mice per group): vehicle, XL-184, HNK, and XL-184 + HNK. Once the palpable tumor growth was observed, mice were treated with XL-184 (15 mg/kg), HNK (2 mg/kg) and XL-14 + HNK every alternate day for three weeks via intraperitoneal injection.
Result	Cabozantinib + Honokiol combination can significantly inhibit c-Met-induced and Nrf2-mediated anti-oxidant pathway in renal cancer cells to promote increased oxidative stress and tumor cell death.

Pair Name	Atractylenolide I, Cabozantinib
Partner Name	Atractylenolide I
Disease Info	[ICD-11: 2C82]	Prostate cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	CASP3	hsa836
	Up-regulation	Expression	CDH1	hsa999
	Up-regulation	Expression	PARP1	hsa142
	Down-regulation	Expression	VIM	hsa7431
In Vitro Model	DU145	Prostate carcinoma	Homo sapiens (Human)	CVCL_0105
In Vitro Model	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
Result	Silencing Hsp27 inhibits EMT. ATL-1 can inhibit the malignant evolution of prostate cancer cells by inhibiting Hsp27/eIF4E. ATL-1 also enhanced chemosensitization of cabozantinib in prostate cancer.